Citations

Showing 10 of 108152 citations.

Genetic and Clinical Studies of Patients With Increased Multinucleated Megakaryocytes in Bone Marrow as an Isolated Finding
Zheng, Gang , He, Rong , Reichard, Kaaren K. , Peterson, Jess F. , Olteanu, Horatiu , Oliveira, Jennifer L. , Rangan, Aruna , Chen, Dong , Herrick, Jennifer L. , Chen, Dong , Peterson, Jess F , Shi, Min

Mayo Clinic

American Journal of Surgical Pathology | May 19, 2021 | Volume: 45 | Issue: 11 | Pages: 1534-1540

10.1097/pas.0000000000001732 | PMID 33999554 Get It

The presence of increased multinucleated megakaryocytes (aka osteoclast-like) is considered a dysplastic feature in myelodysplastic syndrome; however, its clinical significance in isolation is uncertain. Herein, we report the clinicopathologic and genetic features of 18 such cases of 40,539 bone marrow biopsies spanning 10 years. All 18 patients had ≥25% multinucleated megakaryocytes in otherwise normal bone marrow biopsies, which were evaluated for plasma cell neoplasms (n=9), lymphoma (n=4), or anemia/neutropenia (n=5). None of the 17 patients tested showed acquired cytogenetic abnormalities. Sixteen patients underwent targeted gene panel next-generation sequencing: 9 patients had no pathogenic mutations; 3 harbored a single pathogenic mutation with variant allele frequencies of 7.5%, 7.6%, and 10.7%, likely representing clonal hematopoiesis of indeterminate potential; 1 had 2 pathogenic mutations, 1 of which had a variant allele frequency >20%. Fourteen of 18 patients had a follow-up period >6 months (median: 36.5 mo, range: 7 to 110 mo) and no patients developed a new-onset cytopenia, a progressive cytopenia, or a myeloid neoplasm. The patient with 2 mutations had persistent anemia, worrisome for an emerging MDS. However, given the absence of thrombocytopenia, increased multinucleated megakaryocytes in this patient could be an unrelated incidental finding. Our study indicates that increased multinucleated megakaryocytes as an isolated finding is a rare phenomenon, and this sole morphologic finding is not diagnostic of myelodysplastic syndrome. Diagnostic approaches in the presence of increased multinucleated megakaryocytes are proposed based on different clinical and pathologic scenarios.
Transfusion-Associated Immunomodulation in Critically Ill Patients: More Than Just Red Cells?*
Applefeld, Willard N. , Athale, Janhavi, Wang, Jeffrey

Mayo Clinic

Critical Care Medicine | May 19, 2021 | Volume: 49 | Issue: 6 | Pages: 993-995

10.1097/ccm.0000000000004929 | PMID 34011833 Get It

Telehealth Strategies to Support Patients and Families Across the Cancer Trajectory
Mulvey, Therese M. , Peppercorn, Jeffrey , Allen-Watts, Kristen , Bakitas, Marie , Cheville, Andrea , Dionne-Odom, James Nicholas

Mayo Clinic

American Society of Clinical Oncology Educational Book | May 19, 2021 | Volume: No volume available | Issue: 41 | Pages: 413-422

10.1200/edbk_320979 | PMID 34010046 Get It

Effective delivery of cancer care via telehealth requires a planned care system that accounts for myriad patient, provider, and practice/cancer center resources before, during, and after the care episode. Telehealth is broadly defined as a method to have virtual, bidirectional communication between patients and providers. Telehealth can include methods such as audio-only, video-consultation, and tele-monitoring, which can occur in a synchronous, asynchronous, or blended format. The purpose of this review is to present common foundational principles for providing clinical cancer care via telehealth, followed by an overview of three distinct examples of comprehensive telehealth programs that have been developed to meet the needs of patients and families across the cancer trajectory, including survivorship, rehabilitation, and palliative care phases. The programs described are exemplars that were developed and implemented prior to the coronavirus pandemic, so they reflect many years of planning and evidence. Lessons learned include the need for ongoing patient support, clinician training, and cancer health system/practice programmatic considerations such as billing, scheduling, reimbursement, software, and hardware/platform security. Although the COVID-19 pandemic produced an explosive shift in regulations and implementation, sustainability of these changes may not be long-term. Nevertheless, a permanent shift in cancer care to include telehealth is likely here to stay.
Navigating Myelodysplastic and Myelodysplastic/Myeloproliferative Overlap Syndromes
Hasserjian, Robert P. , Buckstein, Rena , Patnaik, Mrinal M.

Mayo Clinic

American Society of Clinical Oncology Educational Book | May 19, 2021 | Volume: No volume available | Issue: 41 | Pages: 328-350

10.1200/edbk_320113 | PMID 34010050 Get It

Myelodysplastic syndromes (MDS) and MDS/myeloproliferative neoplasms (MPNs) are clonal diseases that differ in morphologic diagnostic criteria but share some common disease phenotypes that include cytopenias, propensity to acute myeloid leukemia evolution, and a substantially shortened patient survival. MDS/MPNs share many clinical and molecular features with MDS, including frequent mutations involving epigenetic modifier and/or spliceosome genes. Although the current 2016 World Health Organization classification incorporates some genetic features in its diagnostic criteria for MDS and MDS/MPNs, recent accumulation of data has underscored the importance of the mutation profiles on both disease classification and prognosis. Machine-learning algorithms have identified distinct molecular genetic signatures that help refine prognosis and notable associations of these genetic signatures with morphologic and clinical features. Combined geno-clinical models that incorporate mutation data seem to surpass the current prognostic schemes. Future MDS classification and prognostication schema will be based on the portfolio of genetic aberrations and traditional features, such as blast count and clinical factors. Arriving at these systems will require studies on large patient cohorts that incorporate advanced computational analysis. The current treatment algorithm in MDS is based on patient risk as derived from existing prognostic and disease classes. Luspatercept is newly approved for patients with MDS and ring sideroblasts who are transfusion dependent after erythropoietic-stimulating agent failure. Other agents that address red blood cell transfusion dependence in patients with lower-risk MDS and the failure of hypomethylating agents in higher-risk disease are in advanced testing. Finally, a plethora of novel targeted agents and immune checkpoint inhibitors are being evaluated in combination with a hypomethylating agent backbone to augment the depth and duration of response and, we hope, improve overall survival.
Improving Oncology-Pathology Collaboration in Resource-Limited Settings: An American Society of Clinical Oncology/College of American Pathologists Initiative
Sanchez, Jose Angel , Portillo, Silvia, Zarka, Matthew A., Snedden, Devon, Pyle, Doug, Goodman, Harris S., Hayes, Daniel F.

Mayo Clinic

American Society of Clinical Oncology Educational Book | May 19, 2021 | Volume: No volume available | Issue: 41 | Pages: 199-220

10.1200/edbk_320037 | PMID 34010051 Get It

Accurate pathologic evaluation is essential for proper diagnosis and treatment of patients with cancer. ASCO and the College of American Pathologists have successfully collaborated over the last 15 years to improve collaboration between clinical oncologists and pathologists and to standardize pathologic assay techniques. Cancer is an increasingly recognized societal burden in low- and middle-income countries. In 2015, ASCO and the College of American Pathologists implemented an initiative to identify countries that could benefit from peer insights by jointly convening an international workshop among members of both organizations and pathologists and clinical oncologists from Haiti, Honduras, Vietnam, and Uganda. Honduras was chosen as a pilot site, and representatives of ASCO, the College of American Pathologists, and the Honduras pathology and clinical oncology communities have identified areas in which collaboration might be productive. Multiple barriers, including high poverty levels, poor cancer awareness educational programs, lack of human resources, and delayed diagnosis and treatment, have resulted in a higher cancer mortality rate in Honduras compared with high/moderate-income countries and are shared by other low-income countries. ASCO and the College of American Pathologists member faculty supported a symposium led by Honduras colleagues for interested Honduran pathologists and oncologists. The Honduran communities are now working to establish national resource-appropriate guidelines for both pathology and clinical oncology. Taken together, these efforts indicate that barriers to meet the needs of the clinical oncologists in a low-income country such as Honduras are challenging but not insurmountable.
Consensus-based classification system for intra-operative management of labral tears during hip arthroscopy—aggregate recommendations from high-volume hip preservation surgeons
Lall, Ajay C. , Annin, Shawn , Chen, Jeffrey , Diulus, Samantha C. , Ankem, Hari K. , Shapira, Jacob , Meghpara, Mitchell B. , Hartigan, David E. , Krych, Aaron J. , Levy, Bruce A. , Domb, Benjamin G. , Krych, Aaron J , Domb, Benjamin G , Rosinsky, Philip J. , Maldonado, David R.

Mayo Clinic

Journal of Hip Preservation Surgery | May 19, 2021 | Volume: 7 | Issue: 4 | Pages: 644-654

10.1093/jhps/hnab043 | PMID 34377508 Get It

Abstract The purpose of this study was to survey high-volume hip preservation surgeons regarding their perspectives on intra-operative management of labral tears to improve decision-making and produce an effective classification system. A cross-sectional survey of high-volume hip preservation surgeons was conducted in person and anonymously, using a questionnaire that is repeated for indications of labral debridement, repair and reconstruction given the torn labra are stable, unstable, viable or non-viable. Twenty-six high-volume arthroscopic hip surgeons participated in this survey. Provided the labrum was viable (torn tissue that is likely to heal) and stable, labral debridement would be performed by 76.92% of respondents for patients >40 years of age and by >84% of respondents for stable intra-substance labral tears in patients without dysplasia. If the labrum was viable but unstable, labral repair would be performed by >80% of respondents for patients ≤40 years of age and > 80% of respondents if the labral size was >3 mm and located anteriorly. Presence of calcified labra or the Os acetabuli mattered while deciding whether to repair a labrum. In non-viable (torn tissue that is unlikely to heal) and unstable labra, labral reconstruction would be performed by 84.62% of respondents if labral size was <3 mm. The majority of respondents would reconstruct calcified and non-viable, unstable labra that no longer maintained a suction seal. Surgeons performing arthroscopic hip labral treatment may utilize this comprehensive classification system, which takes into consideration patient age, labral characteristics (viability and stability) and bony morphology of the hip joint. When choosing between labral debridement, repair or reconstruction, consensus recommendations from high-volume hip preservation surgeons can enhance decision-making.
Physical activity and exercise in patients with spontaneous coronary artery dissection and fibromuscular dysplasia
Tweet, Marysia S. , Olin, Jeffrey W. , Bonikowske, Amanda R. , Adlam, David , Hayes, Sharonne N. , Hayes, Sharonne N , Tweet, Marysia S

Mayo Clinic

European Heart Journal | May 19, 2021 | Volume: 42 | Issue: 37 | Pages: 3825-3828

10.1093/eurheartj/ehab307 | PMID 34097033 Get It

Archetypes of Coaching Across the Medical Education Continuum
Love, Linda M., Simonsen, Kari A., Bowler, Carrie, Dallaghan, Gary L. Beck, Simonsen, Kari , Simonsen, Kari A , Love, Linda M., Bowler, Carrie, Dallaghan, Gary L. Beck

Mayo Clinic

Academic Medicine | May 19, 2021 | Volume: 96 | Issue: 12 | Pages: 1757-1757

10.1097/acm.0000000000004169 | PMID 34010866 Get It

Monoclonal Gammopathy of Renal Significance
Leung, Nelson , Nasr, Samih H. , Bridoux, Frank , Leung, Nelson

Mayo Clinic

New England Journal of Medicine | May 19, 2021 | Volume: 384 | Issue: 20 | Pages: 1931-1941

10.1056/nejmra1810907 | PMID 34010532 Get It

Machine-Learning Approach to Differentiation of Benign and Malignant Peripheral Nerve Sheath Tumors: A Multicenter Study
Zhang, Michael , Tong, Elizabeth , Hamrick, Forrest , Lee, Edward H. , Tam, Lydia , Pendleton, Courtney , Smith, Brandon W. , Hug, Nicholas F. , Biswal, Sandip , Seekins, Jayne , Mattonen, Sarah A. , Napel, Sandy , Campen, Cynthia , Spinner, Robert J. , Yeom, Kristen W. , Wilson, Thomas J. , Mahan, Mark A

Mayo Clinic

Neurosurgery | May 19, 2021 | Volume: 89 | Issue: 3 | Pages: 509-517

10.1093/neuros/nyab212 | PMID 34131749 Get It

Abstract BACKGROUND Clinicoradiologic differentiation between benign and malignant peripheral nerve sheath tumors (PNSTs) has important management implications. OBJECTIVE To develop and evaluate machine-learning approaches to differentiate benign from malignant PNSTs. METHODS We identified PNSTs treated at 3 institutions and extracted high-dimensional radiomics features from gadolinium-enhanced, T1-weighted magnetic resonance imaging (MRI) sequences. Training and test sets were selected randomly in a 70:30 ratio. A total of 900 image features were automatically extracted using the PyRadiomics package from Quantitative Imaging Feature Pipeline. Clinical data including age, sex, neurogenetic syndrome presence, spontaneous pain, and motor deficit were also incorporated. Features were selected using sparse regression analysis and retained features were further refined by gradient boost modeling to optimize the area under the curve (AUC) for diagnosis. We evaluated the performance of radiomics-based classifiers with and without clinical features and compared performance against human readers. RESULTS A total of 95 malignant and 171 benign PNSTs were included. The final classifier model included 21 imaging and clinical features. Sensitivity, specificity, and AUC of 0.676, 0.882, and 0.845, respectively, were achieved on the test set. Using imaging and clinical features, human experts collectively achieved sensitivity, specificity, and AUC of 0.786, 0.431, and 0.624, respectively. The AUC of the classifier was statistically better than expert humans ( P = .002). Expert humans were not statistically better than the no-information rate, whereas the classifier was ( P = .001). CONCLUSION Radiomics-based machine learning using routine MRI sequences and clinical features can aid in evaluation of PNSTs. Further improvement may be achieved by incorporating additional imaging sequences and clinical variables into future models.